Karen M. Haas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karen M. Haas has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Caroline B. Dixon
Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
16 shared publications - Dawen Zhao
Department of Cancer Biology, Wake Forest University School of Medicine , Winston-Salem, North Carolina
16 shared publications - Fei Xing
Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA
16 shared publications - George Oliver
Department of Pharmacy, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina
16 shared publications - Jason M. Grayson
Department of Microbiology and Immunology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America
16 shared publications - Jimmy Ruiz
Department of Internal Medicine, Section of Hematology and Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
16 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 94 (10)
DksA-dependent stringent stress response drives virulence and gastrointestinal persistence of Klebsiella pneumoniae
Successful gastrointestinal (GI) colonization by bacterial pathogens requires adaptation to nutrient competition and host-derived stresses in the gut, with adaptation via the bacterial stringent stress response playing a critical role. Epidemiological data suggest that the GI tract serves as a reservoir from which K. pneumoniae can spread and cause invasive disease or transmit to another host. DksA is a conserved stringent response transcriptional regulator that was identified in an in vivo transposon mutagenesis screen as an important K. pneumoniae gut determinant. However, its role in K. pneumoniae pathogenesis and gut colonization remain uncharacterized. Here, we demonstrate that DksA is required for survival against membrane-targeting antibiotics, consistent with a role in cell envelope stress tolerance. In addition, DksA positively influences capsule biosynthesis gene expression and hypermucoviscosity, and is essential for robust biofilm formation. Using a murine model, we establish that DksA functions as a determinant of GI colonization, despite disruption of the resident gut microbiota. Furthermore, we demonstrate that DksA is important for environmental survival and transmission by regulating RpoS, thereby providing a mechanistic link between the stringent stress response, environmental survival, and subsequent transmission. Together, these findings establish DksA as a central integrator of the stringent response, coordinating membrane stress resistance, virulence traits, and gastrointestinal colonization in K. pneumoniae .
- 13 October 2026
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 94 (10)
Open AccessDksA-dependent stringent stress response drives virulence and gastrointestinal persistence of Klebsiella pneumoniae
Successful gastrointestinal (GI) colonization by bacterial pathogens requires adaptation to nutrient competition and host-derived stresses in the gut, with adaptation via the bacterial stringent stress response playing a critical role. Epidemiological data suggest that the GI tract serves as a reservoir from which K. pneumoniae can spread and cause invasive disease or transmit to another host. DksA is a conserved stringent response transcriptional regulator that was identified in an in vivo transposon mutagenesis screen as an important K. pneumoniae gut determinant. However, its role in K. pneumoniae pathogenesis and gut colonization remain uncharacterized. Here, we demonstrate that DksA is required for survival against membrane-targeting antibiotics, consistent with a role in cell envelope stress tolerance. In addition, DksA positively influences capsule biosynthesis gene expression and hypermucoviscosity, and is essential for robust biofilm formation. Using a murine model, we establish that DksA functions as a determinant of GI colonization, despite disruption of the resident gut microbiota. Furthermore, we demonstrate that DksA is important for environmental survival and transmission by regulating RpoS, thereby providing a mechanistic link between the stringent stress response, environmental survival, and subsequent transmission. Together, these findings establish DksA as a central integrator of the stringent response, coordinating membrane stress resistance, virulence traits, and gastrointestinal colonization in K. pneumoniae .
- Open Access
- 17 September 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e015127
IgM promotes antitumor immunity to a Tn-expressing solid tumor
Background: Altered O-glycosylation is a hallmark of many adenocarcinomas and is often characterized by expression of the Tn antigen. However, the role of B cells in protection against Tn-expressing solid tumors remains poorly understood. Methods: We generated a colorectal tumor cell line (CMT93) lacking Cosmc , resulting in high Tn expression. Using mice with defined B-cell abnormalities, including deficiencies in B cells, IgM secretion, natural IgM, and B-cell receptor (BCR) repertoire diversity, we investigated the contribution of B cells and secreted antibody to immunity against Tn-expressing colorectal tumors. Results: Cosmc -deficient tumors grew more rapidly than parental tumors, and IgM deposition was observed within tumors from wild-type mice, suggesting a potential role for antibody in antitumor defense. Tumor-reactive serum IgM, including Tn-reactive IgM, was present in naïve mice. B cell-deficient muMT, V H B 1-8 transgenic mice with a restricted BCR repertoire, CD19 −/− mice deficient in natural IgM, and μS −/− mice unable to secrete IgM, lacked tumor-reactive IgM and showed increased tumor burdens, suggesting a protective role for secreted tumor-reactive IgM. Lack of tumor-reactive IgM in V H B 1-8 transgenic and μS −/− mice was associated with significant alterations in tumor-infiltrating leukocyte composition. Relative to wild-type mice, tumors from V H B 1-8 transgenic and μS −/− mice exhibited significantly increased PD-L1 hi Ly6G + Ly6C − CD11b + myeloid cells, but reduced B, T, and natural killer cells, along with reduced major histocompatibility complex class II expression on tumor-associated dendritic cells. Moreover, tumor draining lymph nodes from V H B 1-8 transgenic and μS −/− mice showed significant reductions in antibody-secreting cells, including IgG + plasmablasts, which corresponded with decreased IgM and IgG deposition on tumors. Conclusions: These findings support a role for B cells and secreted IgM in restraining the growth of Tn-expressing solid tumors and shaping antitumor immunity against tumors with aberrant O-glycosylation.
- 17 September 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e015127
Open AccessIgM promotes antitumor immunity to a Tn-expressing solid tumor
Background: Altered O-glycosylation is a hallmark of many adenocarcinomas and is often characterized by expression of the Tn antigen. However, the role of B cells in protection against Tn-expressing solid tumors remains poorly understood. Methods: We generated a colorectal tumor cell line (CMT93) lacking Cosmc , resulting in high Tn expression. Using mice with defined B-cell abnormalities, including deficiencies in B cells, IgM secretion, natural IgM, and B-cell receptor (BCR) repertoire diversity, we investigated the contribution of B cells and secreted antibody to immunity against Tn-expressing colorectal tumors. Results: Cosmc -deficient tumors grew more rapidly than parental tumors, and IgM deposition was observed within tumors from wild-type mice, suggesting a potential role for antibody in antitumor defense. Tumor-reactive serum IgM, including Tn-reactive IgM, was present in naïve mice. B cell-deficient muMT, V H B 1-8 transgenic mice with a restricted BCR repertoire, CD19 −/− mice deficient in natural IgM, and μS −/− mice unable to secrete IgM, lacked tumor-reactive IgM and showed increased tumor burdens, suggesting a protective role for secreted tumor-reactive IgM. Lack of tumor-reactive IgM in V H B 1-8 transgenic and μS −/− mice was associated with significant alterations in tumor-infiltrating leukocyte composition. Relative to wild-type mice, tumors from V H B 1-8 transgenic and μS −/− mice exhibited significantly increased PD-L1 hi Ly6G + Ly6C − CD11b + myeloid cells, but reduced B, T, and natural killer cells, along with reduced major histocompatibility complex class II expression on tumor-associated dendritic cells. Moreover, tumor draining lymph nodes from V H B 1-8 transgenic and μS −/− mice showed significant reductions in antibody-secreting cells, including IgG + plasmablasts, which corresponded with decreased IgM and IgG deposition on tumors. Conclusions: These findings support a role for B cells and secreted IgM in restraining the growth of Tn-expressing solid tumors and shaping antitumor immunity against tumors with aberrant O-glycosylation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1-16 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer
Supplementary Table 1-16 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1-16 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer
Supplementary Table 1-16 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer
- Open Access
- 12 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Efficacy of Pam3CSK4 as a cross-species adjuvant for polysaccharide vaccines in humanized mouse and non-human primate models
Polysaccharide-based vaccines are essential for preventing bacterial infections, but their effectiveness is limited by weak antibody responses and lack of suitable adjuvants. TLR4 agonists enhance polysaccharide-specific antibody responses through B cell–intrinsic TLR4-MyD88 signaling in mice, but this mechanism is not conserved in primates, prompting the search for alternative MyD88-activating agonists. In vitro, the TLR1/2 agonist Pam3CSK4 synergizes with strong BCR crosslinking to enhance activation and antibody secretion by mouse and human B cells. In vivo, Pam3CSK4 in squalene emulsion increases protective pneumococcal polysaccharide–specific antibody responses in both immunocompetent and humanized mice. Although a dual TLR2/7 agonist shows strong in vitro activity, it fails to enhance polysaccharide-specific IgG responses in vivo, consistent with antagonism observed when Pam3CSK4 and TLR7 agonists are combined. In contrast, incorporating Pam3CSK4 into an adjuvant containing a TLR4 agonist, synthetic cord factor, and squalene emulsion further enhances memory B cell generation and protective antibody responses in mice and restores adjuvant activity in non-human primates, supporting Pam3CSK4-based formulations as promising adjuvants for polysaccharide vaccines.
- 12 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessEfficacy of Pam3CSK4 as a cross-species adjuvant for polysaccharide vaccines in humanized mouse and non-human primate models
Polysaccharide-based vaccines are essential for preventing bacterial infections, but their effectiveness is limited by weak antibody responses and lack of suitable adjuvants. TLR4 agonists enhance polysaccharide-specific antibody responses through B cell–intrinsic TLR4-MyD88 signaling in mice, but this mechanism is not conserved in primates, prompting the search for alternative MyD88-activating agonists. In vitro, the TLR1/2 agonist Pam3CSK4 synergizes with strong BCR crosslinking to enhance activation and antibody secretion by mouse and human B cells. In vivo, Pam3CSK4 in squalene emulsion increases protective pneumococcal polysaccharide–specific antibody responses in both immunocompetent and humanized mice. Although a dual TLR2/7 agonist shows strong in vitro activity, it fails to enhance polysaccharide-specific IgG responses in vivo, consistent with antagonism observed when Pam3CSK4 and TLR7 agonists are combined. In contrast, incorporating Pam3CSK4 into an adjuvant containing a TLR4 agonist, synthetic cord factor, and squalene emulsion further enhances memory B cell generation and protective antibody responses in mice and restores adjuvant activity in non-human primates, supporting Pam3CSK4-based formulations as promising adjuvants for polysaccharide vaccines.